الفهرس Only 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Lung cancer is the leading cause of tumor-related deaths.
Most malignant primary tumors of the lungs (66%) are bronchogenic carcinomas, which represent the most frequent cause of cancer death in males (35%) and females (18%). Lung cancer is a leading cause of death in the world and is responsible for 25% of all cancer death.
Non-small cell lung cancer (NSCLC) accounts for about 80% of bronchogenic malignancies.
conventional chest radiograph, computed tomography (CT), Magnetic resonance imaging (MRI), radionuclide scintigraphy and positron emission tomography all have been used for NSCLC staging.
PET/CT is a unique combination of the cross sectional anatomy provided by CT and the metabolic information provided by PET which are acquired during a single examination and fused.
PET/CT offers several advantages over PET alone; the most important is the ability to accurately localize increased FDG activity to specific normal or abnormal anatomic locations, which may be difficult or even impossible with PET alone due to the absence of identifiable anatomic structures.
PET/CT is superior to CT alone because its PET component depends on the physiologically mediated distribution of glucose uptake, rather than on the anatomic and structural characteristics of tissue.
PET/CT detects lung cancer early with high accuracy, Increases the number of patients with correctly staged NSCLC, has the ability to differentiate between recurrence, residual, operative scar and post irradiation fibrosis and also has a positive effect on treatment with a profound effect on therapy so it is more accurate in patient follow up and prognosis